InPen App, CFN: MMT-8060 (iOS Users) and MMT-8061 (Android Users)
Publicado el 10 de septiembre de 2025 · Inicio del retiro: 16 de junio de 2025
Resumen
FDA registra el retiro Z-2496-2025 de dispositivos médicos de Clase II, publicado el 10 de septiembre de 2025 e iniciado el 16 de junio de 2025. Empresa responsable: Medtronic MiniMed, Inc.; Estado: En curso; Cantidad reportada: 6816; Lote: UDI-DI: 0763000B000122075 CFN/Software Version: MMT-8060/7.0.0, 7.1.0, 7.2.0 and 7.5.0 MMT-8061/7.0.0, 7.0.1, 7.1.0, 7.1.1, 7.2.0 and 7.5.0. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Medtronic MiniMed, Inc. is recalling InPen App for iOS and Android users due to software design errors that could lead to a missed short-acting insulin dose reminder and a recommendation to correct a high glucose value. It does not impact insulin delivery, long-acting insulin dose reminders, or CGM alerts, and users can still use the pen itself to calculate a dose, deliver insulin, record the dose date/time, and view CGM data. This issue was identified during internal testing before release in the US but after release to OUS customers, no complaints or MDRs related to this recall have been reported. Use of the affected device may result hyperglycemia by failing to alert the user and delay treatment of diabetes.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Medtronic MiniMed, Inc.
- Distribuidor
- International distribution to the countries of Argentina, Australia, Austria, Belgium, Bermuda, Chile, Czech Republic, Denmark, Egypt, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, South Africa, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom.
- Lote
- UDI-DI: 0763000B000122075 CFN/Software Version: MMT-8060/7.0.0, 7.1.0, 7.2.0 and 7.5.0 MMT-8061/7.0.0, 7.0.1, 7.1.0, 7.1.1, 7.2.0 and 7.5.0
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAGeneric Name: MiniMed Go App Generic Name: MiniMed Go App Model/Catalog Number: MMT-8600 (iOS), MMT-860128 de octubre de 2026
- FDACareLink Clinic, REF: MMT-735028 de octubre de 2026
- FDABrand Name: MiniMed Flex Product Name: MiniMed Flex Insulin Pump Model/Catalog Numbers: MMT-8062; MMT-807214 de octubre de 2026
- FDAMiniMed 780G Insulin Pump, Model: MMT-1885CLW, MMT-1886CLW26 de agosto de 2026
- FDARayStation with the following product descriptions: 1. RayStation 11A, Software Version: 11.0.0.951. 2.10 de septiembre de 2025
- FDABlood Uric Acid Monitoring System Each kit contains 1 meter, 1 lancing device, user manual, 10 lancets, and 1010 de septiembre de 2025
Preguntas sobre este retiro
¿InPen App, CFN: MMT-8060 (iOS Users) and MMT-8061 (Android Users) fue retirado del mercado?
Sí. FDA publicó el retiro Z-2496-2025 el 10 de septiembre de 2025. Peligro reportado: Medtronic MiniMed, Inc. is recalling InPen App for iOS and Android users due to software design errors that could lead to a missed short-acting insulin dose reminder and a recommendation to correct a high glucose value. It does not impact insulin delivery, long-acting insulin dose reminders, or CGM alerts, and users can still use the pen itself to calculate a dose, deliver insulin, record the dose date/time, and view CGM data. This issue was identified during internal testing before release in the US but after release to OUS customers, no complaints or MDRs related to this recall have been reported. Use of the affected device may result hyperglycemia by failing to alert the user and delay treatment of diabetes.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter